Paul Horstmeier - Dec 6, 2021 Form 4/A - Amendment Insider Report for Health Catalyst, Inc. (HCAT)

Role: Chief Operating Officer
Signature: /s/ Daniel Orenstein, as Attorney-in-Fact
Stock symbol: HCAT
Transactions as of: Dec 6, 2021
Transactions value $: -$141,636
Form type: 4/A - Amendment
Date filed: 12/29/2021, 04:19 PM
Date Of Original Report: Dec 7, 2021
Previous filing: Dec 7, 2021
Next filing: Dec 29, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HCAT	Common Stock	Options Exercise	$96K	+6.06K	+6.11%	$15.84	105K	Dec 6, 2021	Direct	F1
transaction	HCAT	Common Stock	Sale	-$22.8K	-600	-0.57%	$37.97	105K	Dec 6, 2021	Direct	F2, F3
transaction	HCAT	Common Stock	Sale	-$104K	-2.67K	-2.56%	$38.76	102K	Dec 6, 2021	Direct	F2, F4
transaction	HCAT	Common Stock	Sale	-$111K	-2.79K	-2.74%	$39.89	99.2K	Dec 6, 2021	Direct	F2, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HCAT	Stock Option (Right to Buy)	Options Exercise	$0	-6.06K	-10.44%	$0.00	52K	Dec 6, 2021	Common Stock	6.06K	$15.84	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Due to a technical and administrative error, the original Form 4, filed on December 7, 2021, incorrectly reflected a sale of shares of Common Stock by the Reporting Person attributed to a vesting of Restricted Stock Units. We were recently made aware that the Reporting Person exercised options and sold shares from that option exercise. The exercise of those options and sale of shares is correctly reflected herein and the correct ownership tabulations are also included herein.
F2	The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 15, 2020, in accordance with Rule 10b5-1.
F3	Represents the weighted average sale price of the shares sold ranging from $37.47 to $38.43 per share, inclusive.
F4	Represents the weighted average sale price of the shares sold ranging from $38.47 to $39.24 per share, inclusive.
F5	Represents the weighted average sale price of the shares sold ranging from $39.66 to $40.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (3) through (5).
F6	25% of the 186,467 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023.